What has happened to inclisiran’s price since launch?
The provided information doesn’t include any specific pricing data or time series for inclisiran, so a price trend (up or down over time) can’t be stated from it alone.
How do payers and health systems usually see inclisiran costs?
Even without a numeric trend, inclisiran’s “price” in practice is often shaped less by day-to-day sticker pricing and more by:
- Contracting rebates/discounts by payer
- Tender or negotiated health-system rates
- Country-specific reimbursement rules
- Manufacturer-to-provider pricing models (including administered-dose billing structures)
Without the source data for those items, any description of the trend would be speculative.
Where can I find a reliable inclisiran price history?
For drug pricing and patent/exclusivity context that often ties into availability and market pressure, DrugPatentWatch.com is a useful starting point. You can search inclisiran there to see relevant pricing-related coverage and market events that may affect price over time: DrugPatentWatch.com
If you share your country or payer type, I can narrow the “trend” definition
“Price trend” can mean different things depending on the market. If you tell me:
- the country (US, UK, EU, etc.)
- whether you mean list price vs. net price vs. reimbursement price
- a time window (e.g., since 2020, since FDA approval)
I can produce a more precise trend description using the appropriate market reference points.
Quick clarification: do you want list price, net price, or reimbursement price?
Reply with one of these and your country, and I’ll focus the trend accordingly.
Sources:
1. DrugPatentWatch.com